NCT00528216 is a Phase 1 clinical trial of Capsaicin Dermal Liquid in Pain, sponsored by NeurogesX.

Who is sponsoring NCT00528216?

NCT00528216 is sponsored by NeurogesX.

What drugs are being tested in NCT00528216?

Interventions in NCT00528216: Capsaicin Dermal Liquid.

Is NCT00528216 still recruiting?

NCT00528216 is currently completed. Last updated 4 March 2008.

Last reviewed 2008-03-04 · How we verify

NCT00528216

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Randomized, Controlled, Single-Blind Study to Investigate the Effect of Three Capsaicin Dermal Liquid Formulations on Epidermal Nerve Fiber Immunostaining and Sensory Function In Healthy Volunteers

Completed Phase 1 Last updated 4 March 2008

What this trial tests

Phase 1 trial testing Capsaicin Dermal Liquid in Pain in 20 participants. Completed.

Quick facts

Lead sponsor	NeurogesX
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	single group
Masking	single
Primary purpose	treatment
Enrollment	20

Drugs / interventions tested

Capsaicin Dermal Liquid — full drug profile →

Conditions studied

Pain — all drugs for Pain →

Sponsor

NeurogesX — full company profile →

Who can join

Adults 18 to 40, any sex, with Pain. Healthy volunteers can join.

Sponsor's own description

The purpose of this study is to evaluate potential changes in epidermal nerve fiber immunostaining (ENFI) and sensory nerve function in healthy normal volunteers following single applications of three different investigational topical Capsaicin Dermal Liquids (10% w/v trans capsaicin), and a comparable control (propylene glycol). In addition, the pain and tolerability of the application of each formulation will also be assessed. Data from this clinical study may be used to select a formulation for further clinical evaluation.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Capsaicinoids in the treatment of neuropathic pain: a review.
Peppin JF, Pappagallo M. · · 2014 · cited 68× · PMID 24409200 · DOI 10.1177/1756285613501576

Verify or expand the search:

Other recruiting trials for Pain

Currently open trials in the same condition.

NCT07533409 — Tactile and Pain Sensory Thresholds and Hand Grip Strength · recruiting
NCT07294092 — Ketamine and Propofol NeuroImaging · EARLY_PHASE1 · recruiting
NCT07290205 — Remimazolam NeuroImaging · EARLY_PHASE1 · recruiting
NCT07487610 — Relationship Between Neuropathic Pain and Geriatric Assessment Parameters in Patients Aged 80 Years and Older · recruiting
NCT07454993 — The Effect of Music During Colonoscopy · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00528216 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by NeurogesX
Last refreshed: 4 March 2008

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00528216.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing